Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study. Fagard C, et al. Among authors: phillips r. Arch Intern Med. 2003 May 26;163(10):1220-6. doi: 10.1001/archinte.163.10.1220. Arch Intern Med. 2003. PMID: 12767960 Free article.
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Plana M, et al. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9. doi: 10.1097/00126334-200407010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15213562
Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.
Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Böni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Günthard HF; Swiss HIV Cohort Study. Joos B, et al. Among authors: phillips re. J Virol. 2005 Jul;79(14):9026-37. doi: 10.1128/JVI.79.14.9026-9037.2005. J Virol. 2005. PMID: 15994796 Free PMC article.
Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.
Oxenius A, McLean AR, Fischer M, Price DA, Dawson SJ, Hafner R, Schneider C, Joller H, Hirschel B, Phillips RE, Weber R, Günthard HF; Swiss HIV Cohort Study Group. Oxenius A, et al. Among authors: phillips re. J Virol. 2002 Oct;76(20):10169-76. doi: 10.1128/jvi.76.20.10169-10176.2002. J Virol. 2002. PMID: 12239291 Free PMC article.
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE. Oxenius A, et al. Among authors: phillips re. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. doi: 10.1073/pnas.202372199. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370434 Free PMC article. Clinical Trial.
HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load.
Oxenius A, Price DA, Hersberger M, Schlaepfer E, Weber R, Weber M, Kundig TM, Böni J, Joller H, Phillips RE, Flepp M, Opravil M, Speck RF; Swiss HIV Cohort Study. Oxenius A, et al. Among authors: phillips re. J Infect Dis. 2004 Apr 1;189(7):1199-208. doi: 10.1086/382028. Epub 2004 Mar 17. J Infect Dis. 2004. PMID: 15031788 Free article.
5,549 results